Headline oocyte: Peru authorizes over S/ 1.7 million for HPV vaccine purchase
Subheadline: The Ministry of Health of Peru initiates a strategic move to acquire vaccines against the Human Papillomavirus (HPV), aiming to safeguard public health.
Article body:
The Peruvian Ministry of Health (Minsa) has authorized the transfer of funds totaling over S/ 1.7 million to the Pan American Health Organization (PAHO), earmarked for the purchase of vaccines against the Human Papillomavirus (HPV). This initiative is part of the Ministry’s comprehensive health strategy, as published in an extraordinary edition of El Peruano, the official state newspaper.
The resolution, signed by Minsa minister César Vásquez, stipulates that the funds are allocated under a "Technical Cooperation Agreement" for the acquisition of vaccines, syringes, and related supplies. This agreement is set to expire on December 31 of this year, implying that the procurement process should be expedited accordingly.
The request for this transfer was made by the National Center for Strategic Resources Supply (Cenares), citing the necessity of these vaccines for the Ministry’s strategic interventions.
The World Health Organization (WHO) recommends the use of the quadrivalent HPV vaccine, designed to protect against four specific types of HPV: 6, 11, 16, and 18. Types 16 and 18 are responsible for approximately 70% of cervical cancer cases, while types 6 and 11 cause around 90% of genital warts.
The WHO also advises that girls aged between 9 and 14 years should receive the HPV vaccine before initiating sexual activity to ensure optimal protection. For immunocompromised individuals (including those with HIV), three doses are recommended, with a minimum of two doses if only two can be administered, separated by an interval of at least 6 months.
HPV, a common viral infection, often remains asymptomatic in many infected individuals. However, when symptoms do appear, they can vary depending on the HPV type and the condition it causes. Common symptoms include:
-
Genital warts: Small, flesh-colored bumps or lesions in the genital area, anus, or mouth. They may be flat, raised, or cauliflower-like, and can cause discomfort, itching, or skin irritation.
- Precancerous or cancerous lesions: High-risk HPV types, such as 16 and 18, are associated with lesions that can lead to cancer, affecting the cervix, vagina, vulva, anus, or penis. Women may not experience symptoms initially, but advanced cases can lead to unusual vaginal bleeding, pelvic pain, or abnormal discharge. In men, changes in penile or anal skin may be observed, but penile cancer is relatively rare.
Peru’s initiative to purchase and distribute HPV vaccines underscores its commitment to preventive healthcare and disease reduction. By vaccinating young individuals, the country aims to decrease the prevalence of HPV-related diseases, including cervical cancer, and enhance overall public health.
The vaccine against the Human Papillomavirus (HPV) is recommended for both girls and boys between the ages of 9 and 14, before they become sexually active. This initiative also aligns with Peru’s commitment to meeting international health standards and obligations.
